These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
18. Transdermal physostigmine in the treatment of Alzheimer's disease. Levy A; Brandeis R; Treves TA; Meshulam Y; Mawassi F; Feiler D; Wengier A; Glikfeld P; Grunwald J; Dachir S Alzheimer Dis Assoc Disord; 1994; 8(1):15-21. PubMed ID: 8185877 [TBL] [Abstract][Full Text] [Related]
19. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716 [TBL] [Abstract][Full Text] [Related]
20. Physostigmine in Alzheimer's disease. Smith CM; Swash M Lancet; 1979 Jan; 1(8106):42. PubMed ID: 83485 [No Abstract] [Full Text] [Related] [Next] [New Search]